Drug intelligence / Profile preview

Metabolic Target 2

Development stage: Preclinical
Lead developer: SatyaRx Pharma Innovations
Modality: Small Molecules

Overview

Metabolic Target 2 is a preclinical-stage small molecule drug candidate being developed by SatyaRx Pharma Innovations for the treatment of metabolic-associated steatohepatitis (MASH). While the specific molecular target remains undisclosed, the program focuses on modulating metabolic pathways to address the underlying pathology of MASH, a progressive form of non-alcoholic fatty liver disease characterized by liver inflammation and damage. The candidate is currently undergoing preclinical evaluation to establish its efficacy and safety profile.

Beyond the preview

Go deeper on Metabolic Target 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metabolic Target 2.

Explore the full profile